• The Compounded Risk Of Early-Stage Biopharma Licensing Deals

    For emerging biopharma firms, licensing options can equal a boon to the business when cash runways are short and financing options run thin. But, there’s a catch. Most licensed candidates fail. And, according to a new paper, rushed licensing deals on the heels of phase 3 clinical failures only compound the disappointment.


Matthew Pillar

Matthew Pillar is chief editor at BioProcess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at